CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet, ACARIZAX®, has been approved in Canada.
The New Drug Submission (NDS) for ACARIZAX® was filed with Health Canada in May 2016. ACARIZAX® is indicated as allergy immunotherapy for the treatment of moderate to severe house dust mite-induced allergic rhinitis, with or without conjunctivitis, in adults 18 to 65 years of age confirmed by a positive skin prick test and/or in vitro testing for D. farinae or D. pteronyssinus IgE antibodies.
Henrik Jacobi, ALK’s Executive Vice President, Research and Development, said: “This new approval expands ALK’s SLIT-tablet range in Canada, which now covers grass, ragweed and, the most common of all respiratory allergies, house dust mite. We continue to develop our organisation and launch readiness in North America ahead of the introduction of the HDM SLIT-tablet.”
ACARIZAX® is currently approved in 18 countries worldwide and launched in nine. Registration reviews are underway in a further eight countries with further submissions planned.
ALK-Abelló A/S
For further information please contact:
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.
http://www.globenewswire.com/NewsRoom/AttachmentNg/36640687-4854-400a-b165-434b0e60920f
